LSE:IBT - How has International Biotechnology Trust been affected by the wave of takeovers across the biotechnology sector, and what did its most recent half-year report reveal about performance? Announcements during 2026 show that mergers and acquisitions have been a recurring theme in its portfolio.
What the trust does
International Biotechnology Trust PLC is a London-listed Investment trust that invests in biotechnology and related companies. Its portfolio managers are Ailsa Craig and Marek Poszepczynski, with Schroder Investment Management Limited acting as alternative investment Fund Manager and company secretary. The trust also holds interests in Venture Capital funds managed by SV Health Investors LLP, giving it exposure to both quoted and unquoted businesses.
Performance is measured against the Nasdaq Biotechnology Index. The trust pays dividends under a policy set at "4% of the Company's NAV as at the last day of the preceding financial year ending 31 August", which means income is linked to asset value rather than to portfolio earnings. Like other investment trusts, its shares can trade at a discount or premium to Net Asset Value (NAV) per share.
Half-year results
On 12 May 2026, the trust published its half-year report for the six months to 28 February 2026. It reported a NAV per share of 988.50p and a NAV total return of 35.7%, ahead of the 29.5% total return from the NASDAQ Biotechnology Index. The share price total return was 39%, and the discount narrowed to 6.7% from 8.9%. Net Assets were £315.4 million.
A first interim Dividend of 15.64p per share was paid on 23 January 2026. During the half, the trust repurchased 1,824,657 shares into treasury, and had a bank Loan of £29.8 million at the period end.
The report noted "Five portfolio company acquisitions during this period, bringing the total number of portfolio companies acquired since 2020 to 35." Leading contributors included uniQure, Vera Therapeutics and Terns Pharmaceuticals, while Soleno Therapeutics was the main detractor, following challenges with its Prader-Willi syndrome launch.
Takeovers continue
Further deals were announced after the period end. On 31 March 2026, the trust said portfolio company Apellis was being acquired by Biogen. On 7 April 2026, it reported that Soleno was being acquired by Neurocrine, and on 29 April 2026 it announced that KalVista was being acquired by Chiesi. For a trust that owns many mid-sized drug developers, bids from larger pharmaceutical and biotechnology groups can crystallise value quickly.
Daily NAV announcements indicate that the portfolio has continued to perform. The trust's RNS dated 4 September 2026 reported NAV per share figures above 1,200p as at 3 September 2026, compared with 988.50p at the end of February. The trust's financial year ends on 31 August, so full-year results covering this period are still to come.
Risks and uncertainties
Biotechnology is a volatile sector. Clinical trial failures, regulatory decisions and commercial launch difficulties can sharply affect individual holdings, as the Soleno example shows. Takeovers can boost returns but also remove successful companies from the portfolio, requiring reinvestment. Its benchmark is a US index and many named holdings are US-listed businesses, so movements in the US dollar against sterling affect reported NAV. Unquoted venture investments are valued less frequently, and gearing through the bank loan can amplify both gains and losses. The managers' outlook suggested that "More profitable, later stage, commercial biotechnology companies should prove more resilient" amid geopolitical tensions.
Conclusion
Company announcements show that acquisitions of portfolio companies have been a meaningful contributor to International Biotechnology Trust's returns, alongside strong clinical and commercial progress at selected holdings. The half-year to February 2026 delivered NAV outperformance against the benchmark, and subsequent NAV updates point to further gains, though the sector's inherent Volatility remains a central consideration.






Please wait processing your request...